While the ultimate litigation effects of the COVID-19 pandemic remain to be seen, the current high-profile healthcare claims are as varied as product liability and mass tort actions, antitrust and patent cases, and disputes involving the Affordable Care Act.
According to the DOJ, this is the ninth consecutive year that the organizations' civil healthcare fraud settlements and judgments have exceeded $2 billion.
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
These transactions best exemplify the most significant trends in the life sciences and biotech space.
The Life Sciences Law Firm Index identifies the most active and relevant firms for life science companies.
Still recovering from a market correction two years ago, and with a scarcity of attractive targets and ongoing macroeconomic uncertainty, the life sciences dealmaking space is in a state of flux.
After a relatively slow 2016 for life sciences deals...
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
Last year proved a slow one for dealmaking in the life sciences space. But that didn’t stop two of the major legal players in it from consummating one themselves: In November, Arnold & Porter and Kaye Scholer agreed to merge, bringing together two formidable healthcare practices.
One year ago, in collaboration with Lake Whillans and our sister site MedCity News, we launched the inaugural Life Sciences Law Firm Index to recognize law firms that are the most active and relevant for life science companies. Over the course of 2016, we have published updates to the Index, each focusing on a different practice area. Today, […]
In January 2016, in collaboration with Lake Whillans and our sister site Above the Law, we published the inaugural Life Sciences Law Firm Index to help identify which law firms are the most active and relevant for life science companies. The goal of the Index is to inform innovators about which firms are the leaders in the […]
Lake Whillans is providing financial relief to insurance companies that offered plans on the Affordable Care Act’s health insurance exchanges and are now impaired by the government’s delay in making promised so-called “risk corridor payments.”
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
When it comes to fighting disease, Michael Shuster takes things personally...
This independent editorial series on healthcare and the law is sponsored by Lake Whillans, a distressed venture capital and litigation finance firm that helps companies facing litigation or arbitration. As states began to jump onto the pharmaceutical regulation bandwagon around the turn of the century, Porzio Bromberg & Newman brought John Ohoro on to help clients sift […]
Not too long ago, it didn’t take much for someone with an idea for a new medical device to rake in the early-stage funding. Investors have been a bit more discerning over the past decade, to say the least, and by and large they remain so, according to K&L Gates’ Michael Hedge, who’s been around long enough to […]
Throughout the year Lake Whillans, with the help of MedCity News, has explored two key issues for healthcare investors and entrepreneurs: trust and reliability. We’ve helped bring to light some harrowing war stories of partnerships gone bad. We’ve also asked healthcare leaders in the trenches about the best ways to operate in the modern healthcare […]